Clarity For Celgene On Revlimid, A Backbone Of MM Treatment
Celgene reached a patent settlement with generic rival Natco that will allow entry of generic lenalidomide in March 2022, but only a limited quantity initially.
Celgene reached a patent settlement with generic rival Natco that will allow entry of generic lenalidomide in March 2022, but only a limited quantity initially.